For cutaneous melanoma the combination of BRAF V600 and NRAS Q61 mutation targets in the custom panel was predicted to cover 60% of patients [skin cutaneous melanoma TCGA dataset (45, 46)]. The gene discussed is BRAF; the disease is cutaneous melanoma.